P189 Bimekizumab in patients with psoriatic arthritis with prior inadequate response to TNF inhibitors: improvements of PsARC over 16 weeks in the Phase 3 BE COMPLETE trial
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.230
Abstract: Bimekizumab (BKZ) is a humanised monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A and has demonstrated clinical effectiveness in both joint and skin outcomes in patients with active psoriatic arthritis (PsA). Psoriatic… read more here.
Keywords: ucb pharma; psoriatic arthritis; pfizer; response ... See more keywords
P193 Bimekizumab improves key symptoms, disease activity and function in patients across the full spectrum of axial spondyloarthritis up to week 24: results from two phase 3 studies
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.234
Abstract: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ demonstrated rapid and clinically meaningful improvements in disease activity across the full spectrum of axial spondyloarthritis (axSpA; active non-radiographic… read more here.
Keywords: ucb pharma; grants research; pharma; axspa ... See more keywords
P194 Bimekizumab is associated with improvement in quality of life in patients across the full spectrum of axial spondyloarthritis at week 16: results from two phase 3 studies
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.235
Abstract: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A and has demonstrated rapid and clinically meaningful improvements in disease activity (ASAS40, primary outcome measure) in patients across the full… read more here.
Keywords: ucb pharma; improvement; pharma; axspa ... See more keywords
FRI0179 Minimal to no transfer of certolizumab pegol into breast milk: results from cradle, a prospective, postmarketing, multicenter, pharmacokinetic study
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.2467
Abstract: Background Women with active chronic rheumatic inflammatory conditions (RA, PsA, AxSpA) often face uncertainty regarding the safety of the use of biologics during breastfeeding.1 Limited and non-validated data exist on the potential transfer of anti-TNFs… read more here.
Keywords: czp; ucb pharma; breast milk; pharma ... See more keywords
FRI0692 Anti-tnf treatments for women with chronic inflammatory diseases: comparing attitudes and perceptions of physicians in europe and the us
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.1919
Abstract: Background: For Women of Childbearing Age (WoCBA) with chronic inflammatory diseases (CID), onset, diagnosis and treatment initiation often overlap with peak reproductive years. High disease activity is associated with increased risk of pregnancy complications and… read more here.
Keywords: pregnancy; ucb pharma; anti tnf; anti tnfs ... See more keywords
LB0001 Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.7889
Abstract: Background Dual neutralisation of IL-17F, in addition to IL-17A, reduces inflammation1 to a greater extent than inhibition of IL-17A alone in disease–relevant cell models. Bimekizumab, a monoclonal antibody that potently and selectively neutralises both IL-17A… read more here.
Keywords: week; pfizer; ucb pharma; bimekizumab ... See more keywords
FRI0397 EFFICACY AND SAFETY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL: RESULTS FROM THE 48-WEEK RUN-IN PART OF C-OPTIMISE
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.3053
Abstract: Background C-OPTIMISE is the first trial to evaluate whether certolizumab pegol (CZP) can be reduced/discontinued in patients with radiographic(r)-axSpA/ankylosing spondylitis (AS) and non-radiographic(nr)-axSpA achieving sustained remission after 48 weeks’ (wks’) treatment. Objectives Here, we report… read more here.
Keywords: part; ucb pharma; novartis; employee ... See more keywords
OP0108 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAÏVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.4883
Abstract: Background IL-17F shares structural homology and pro-inflammatory function with IL–17A. Preclinical and early clinical data support neutralisation of IL-17F, in addition to IL–17A, as a novel targeting approach in psoriatic disease. Objectives The objective of… read more here.
Keywords: response; bkz; ucb pharma; active psa ... See more keywords
OP0103 DOES GENDER, AGE OR SUBPOPULATION INFLUENCE THE MAINTENANCE OF CLINICAL REMISSION IN AXIAL SPONDYLOARTHRITIS FOLLOWING CERTOLIZUMAB PEGOL DOSE REDUCTION?
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.2361
Abstract: Previous studies have shown that withdrawing tumour necrosis factor inhibitors (TNFi) in patients (pts) with axial spondyloarthritis (axSpA) who have achieved sustained remission often leads to relapse.1However, none have formally tested TNFi dose reduction strategies… read more here.
Keywords: maintenance; ucb pharma; pfizer ucb; novartis ... See more keywords
SAT0630-HPR EFFECTS OF GOLIMUMAB ON WORK PRODUCTIVITY AMONG WORK-ACTIVE ANKYLOSING SPONDYLITIS, NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS PATIENTS IN GREECE: THE ‘GO-UP’ STUDY
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.5572
Abstract: Background: Golimumab is a tumor necrosis inhibitor (TNFi) approved for the treatment of axial SpA (axSpA) and psoriatic arthritis (PsA), both falling under the Spondyloarthritis (SpA) domain. Real-world data regarding its effect on work productivity… read more here.
Keywords: grant research; ucb pharma; research support; pharma ... See more keywords
POS0897 REDUCTION OF ANTERIOR UVEITIS FLARES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS DURING CERTOLIZUMAB PEGOL TREATMENT: 96-WEEK RESULTS FROM THE C-VIEW STUDY
Sign Up to like & getrecommendations! Published in 2021 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2021-eular.115
Abstract: Acute anterior uveitis (AAU) is the most common extra-articular manifestation in axial spondyloarthritis (axSpA), affecting up to 40% of patients and causing significant burden.1 Previous studies have shown that tumour necrosis factor inhibitors (TNFi) can… read more here.
Keywords: aau; treatment; ucb pharma; week ... See more keywords